Cardinal Health (CAH)
(Delayed Data from NYSE)
$93.74 USD
-0.36 (-0.38%)
Updated Jul 15, 2024 04:00 PM ET
After-Market: $93.76 +0.02 (0.02%) 4:56 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$93.74 USD
-0.36 (-0.38%)
Updated Jul 15, 2024 04:00 PM ET
After-Market: $93.76 +0.02 (0.02%) 4:56 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
Zacks News
Staar Surgical (STAA) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Staar Surgical (STAA) delivered earnings and revenue surprises of 76.19% and 1.97%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Is Invesco Defensive Equity ETF (DEF) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DEF
Cardinal Health (CAH) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Cardinal Health (CAH) closed at $75.90, marking a -1.61% move from the previous day.
Cardinal Health (CAH) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Cardinal Health's (CAH) first-quarter fiscal 2023 results are likely to reflect solid performance in the Pharmaceutical segment. However, inflation and supply chain constraints are likely to have continued.
Should Invesco Defensive Equity ETF (DEF) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DEF
Analysts Estimate Cardinal Health (CAH) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Cardinal (CAH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cardinal Health (CAH) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Cardinal Health (CAH) closed the most recent trading day at $73.72, moving -0.11% from the previous trading session.
Zacks.com featured highlights include American Airlines, Delta Air Lines, CVR Energy, Bunge Ltd. and Cardinal Health
by Zacks Equity Research
American Airlines, Delta Air Lines, CVR Energy, Bunge Ltd. and Cardinal Health are part of Zacks Screen of the Week article.
Should Invesco S&P Ultra Dividend Revenue ETF (RDIV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for RDIV
Check 5 Broker-Friendly Stocks for Returns Amid Market Chaos
by Maharathi Basu
Broker-favorite stocks like American Airlines (AAL), Delta (DAL), CVR Energy (CVI), Bunge Limited (BG) and Cardinal Health (CAH) should be on an investor's watch list.
Should SPDR Portfolio S&P 500 High Dividend ETF (SPYD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SPYD
Cardinal Health (CAH) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Cardinal Health (CAH) closed at $68.22, marking a +0.21% move from the previous day.
Here's Why You Should Retain Cardinal Health (CAH) Stock Now
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and a diversified product portfolio. However, the cost of products continues to rise.
Is SPDR Portfolio S&P 500 High Dividend ETF (SPYD) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for SPYD
Is WisdomTree U.S. MidCap Dividend ETF (DON) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DON
Seeking Income? Consider These 3 Dividend Aristocrats
by Derek Lewis
During times of heightened volatility, an established income stream is undoubtedly a major positive, allowing investors to offset losses in other positions and reap those sweet dividend payouts.
Cardinal Health (CAH) Lowers Medical Segment Income Guidance
by Zacks Equity Research
Cardinal Health (CAH) projects Medical segment loss to be in the range of $25 million to $55 million for the first quarter of fiscal 2023, owing to inventory charges related to the company's gloves portfolio.
Here's Why You Should Retain Cardinal Health (CAH) Stock Now
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and a diversified product portfolio. However, the cost of products continues to rise.
Company News for Aug 16, 2022
by Zacks Equity Research
Companies In The News Are: DIS, CAH, U, APP, TSLA.
Cardinal Health (CAH) Q4 Earnings Lag Estimates, Revenues Top
by Zacks Equity Research
Cardinal Health's (CAH) fiscal fourth-quarter results benefit from a solid performance in the Pharmaceutical segment.
Cardinal Health (CAH) Lags Q4 Earnings Estimates
by Zacks Equity Research
Cardinal (CAH) delivered earnings and revenue surprises of -10.26% and 5.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Staar Surgical (STAA) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Staar Surgical (STAA) delivered earnings and revenue surprises of 68% and 1.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Invacare (IVC) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Invacare (IVC) delivered earnings and revenue surprises of -20.45% and 11.09%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Cardinal Health (CAH) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Cardinal Health's (CAH) fiscal fourth-quarter results are likely to reflect solid performance in the Pharmaceutical segment. However, inflation and supply chain constraints are likely to have continued.
Cardinal Health (CAH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Cardinal (CAH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.